JianJun Jia

Dr. JianJun Jia


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2019 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
PDF file
WZWeiyi Zeng
Weiyi Zeng
YCYaojing Chen
Yaojing Chen
ZZZhibao Zhu
Zhibao Zhu
SGShudan Gao
Shudan Gao
JXJianan Xia
Jianan Xia
ZZZhanjun Zhang
Zhanjun Zhang
White matter hyperintensity (WMH) is a common finding in aging population and considered to be a contributor to cognitive decline. Our study aimed to characterize the spatial patterns of WMH in different severities and explore its impact on cognition and brain microstructure in non-demented elderly. Lesions were both qualitatively (Fazekas scale) and quantitatively assessed among 321 community-dwelled individuals with MRI scanning. Voxel- and atlas-based analyses of the whole-brain white matter microstructure were performed. The WMH of the same severities was found to occur uniformly with a specific pattern of lesions. The severity of WMH had a significant negative association with the performance of working and episodic memory, beginning to appear in Fazekas 3 and 4. The white matter tracts presented significant impairments in Fazekas 3, which showed brain-wide changes above Fazekas 4. Lower FA in the superior cerebellar peduncle and left posterior thalamic radiation was mainly associated with episodic memory, and the middle cerebellar peduncle was significantly associated with working memory. These results support that memory is the primary domain to be affected by WMH, and the effect may potentially be influenced by tract-specific WM abnormalities. Fazekas scale 3 might be the critical stage predicting a future decline in cognition.

21 April 2023 in Science Advances
Verified
Journal Article
Open access
LZLan-Ting Zhou
Lan-Ting Zhou
DLDan Liu
Dan Liu
HKHuicong Kang
Huicong Kang
LLLu Lu
Lu Lu
HHHe-Zhou Huang
He-Zhou Huang
LZLing-Qiang Zhu
Ling-Qiang Zhu
The neuron-glia cross-talk is critical to brain homeostasis and is particularly affected by neurodegenerative diseases. How neurons manipulate the neuron-astrocyte interaction under pathological conditions, such as hyperphosphorylated tau, a pathological hallmark in Alzheimer’s disease (AD), remains elusive. In this study, we identified excessively elevated neuronal expression of adenosine receptor 1 (Adora1 or A1R) in 3×Tg mice, MAPT P301L (rTg4510) mice, patients with AD, and patient-derived neurons. The up-regulation of A1R was found to be tau pathology dependent and posttranscriptionally regulated by Mef2c via miR-133a-3p. Rebuilding the miR-133a-3p/A1R signal effectively rescued synaptic and memory impairments in AD mice. Furthermore, neuronal A1R promoted the release of lipocalin 2 (Lcn2) and resulted in astrocyte activation. Last, silencing neuronal Lcn2 in AD mice ameliorated astrocyte activation and restored synaptic plasticity and learning/memory. Our findings reveal that the tau pathology remodels neuron-glial cross-talk and promotes neurodegenerative progression. Approaches targeting A1R and modulating this signaling pathway might be a potential therapeutic strategy for AD.

1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
XSXuan Sun
Xuan Sun
JTJiping Tan
Jiping Tan
HSHui Sun
Hui Sun
YLYan Liu
Yan Liu
WGWeiping Guan
Weiping Guan
ZWZhenfu Wang
Zhenfu Wang
Sun X, et al. J Clin Neurol. 2020 Oct;16(4):530-546. https://doi.org/10.3988/jcn.2020.16.4.530

29 May 2021 in Neuroscience Bulletin
Verified
Journal Article
Open access
PDF file
JJJianJun Jia
JianJun Jia
JXJun Xu
Jun Xu
JLJun Liu
Jun Liu
YWYongjun Wang
Yongjun Wang
YWYanjiang Wang
Yanjiang Wang
EYEnyan Yu
Enyan Yu
Alzheimer's disease (AD) is the most common cognitive disorder in the elderly. Its main clinical manifestations are cognitive decline (C), behavioral and psychological symptoms (B), and a decline in the activities of daily living (A), also known as ABC symptoms. Early identification and evaluation of ABC symptoms are helpful for establishing the accurate diagnosis, comprehensive treatment, and prognosis of AD. To guide Chinese clinical practice for optimization of the comprehensive management of AD, in 2018, The Academy of Cognitive Disorder of China gathered 22 neurologists and gerontologists in China to build a consensus on the comprehensive management of AD. Based on a review of the evidence, the consensus summarizes the pathogenesis, pathological changes, clinical manifestations, evaluation, diagnosis, drug and non-drug treatment, and patient care for AD. Focus group discussion was used to establish a flowchart of comprehensive ABC management for AD patients. The new consensus provides a feasible AD management process for clinicians.

2 December 2019 in Neuroscience Bulletin
Verified
Journal Article
Closed access
PDF file
A(Academy Of Cognitive Disorders Of China (Acdc)
Academy Of Cognitive Disorders Of China (Acdc)
YHYuliang Han
Yuliang Han
JJJianJun Jia
JianJun Jia
XLXia Li
Xia Li
YLYang Lv
Yang Lv
YZYuying Zhou
Yuying Zhou

3 October 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XZXiao-Xue Zhang
Xiao-Xue Zhang
MWMeng Wei
Meng Wei
HWHe-Ran Wang
He-Ran Wang
YHYa-Zhuo Hu
Ya-Zhuo Hu
HSHong-Mei Sun
Hong-Mei Sun
JJJianJun Jia
JianJun Jia
Mitochondrial dysfunction (MD) is increasingly recognized as a key pathophysiological contributor in Alzheimer disease (AD). As differential MD genes expression may serve as either a causative factor or a consequence in AD, and expression of these genes could be influenced by epigenetic modifications or interact with inflammatory cytokines, hence, the precise role of MD in AD remains uncertain. Meta-analysis of brain transcriptome datasets was conducted to pinpoint differentially expressed genes (DEGs) associated with MD in AD. We utilized three-step SMR to analyze the AD genome-wide association study summaries with expression quantitative trait loci (eQTLs) and DNA methylation QTLs from the blood and brain tissues, respectively. Through SMR and colocalization analysis, we further explored the interactions between brain eQTLs and inflammatory cytokines. Five datasets were meta-analyzed to prioritize 825 DEGs in AD from 1339 MD-related genes. Among these, seven genes from blood samples such as NDUFS8 and SPG7 and thirty-two genes from brain tissue including CLU and MAPT were identified as candidate AD-causal MD genes and regulated by methylation level. Furthermore, we revealed 13 MD gene expression-inflammatory pathway pairs involving LDLR, ACE and PTPMT1 along with interleukin-17C, interleukin-18 and hepatocyte growth factor. This study highlighted that the AD-causal MD genes could be regulated by epigenetic changes and interact with inflammatory cytokines, providing evidence for AD prevention and intervention.